Research and development of radiation therapy in clinical routines

Acta Oncologica

Volumn 42, Issue 2, 2003, Pages 115-122

  Zackrisson, Björn ^a   Mattsson, Sören ^b   Kjellén, Elisabeth ^b   Glimelius, Bengt ^c,d   Brahme, Anders ^e   Carlsson, Jörgen ^e   Forssell Aronsson, Eva ^e   Hellström, Mikael ^e   Johansson, Karl Axel ^e   Littbrand, Bo ^e   Nordenskjöld, Bo ^e   Stenerlöw, Bo ^e   Turesson, Ingela ^e  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

QUALITY ASSURANCE; QUALITY CONTROL; TUMORS;

CLINICAL ROUTINES;

RADIOTHERAPY;

CANCER RADIOTHERAPY; CANCER RESEARCH; COMPETENCE; MEDICAL SOCIETY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SWEDEN; TREATMENT INDICATION;

CLINICAL COMPETENCE; CLINICAL TRIALS; HUMANS; NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIATION ONCOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; SWEDEN;

EID: 0012688329     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004977     Document Type: Review

References (30)

1. Frödin JE, Jonsson E, Möller T, et al. Radiotherapy in Sweden - a study of present use in relation to the literature and estimate of future trends. Acta Oncol 1996; 35: 967-80.
2. Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659-67.
3. Turesson I, Carlsson J, Brahme A, Glimelius B, Zackrisson B, Stenerlöw B, and the Swedish Cancer Society Investigation Group. Biological response to radiation therapy. Acta Oncol 2003; 42: 92-106.
4. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types - summary and conclusions. Acta Oncol 2001; 40: 135-54.
5. Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40: 253-81.
6. Hellman S. Technology, biology and traffic. Acta Oncol 2001; 40: 679-81.
7. Sorenson S, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 2001; 40: 327-39.
8. Johansson K-A, Mattsson S, Brahme A, Glimelius B, Zackrisson B, Turesson I, and the Swedish Cancer Society Investigation Group. Radiation therapy dose delivery. Acta Oncol 2003; 42: 85-91.
9. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002; 62: 51-60.
10. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000; 55: 317-24.
11. Chow E, Fung K, Panzarella T, et al. A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 2002; 53: 1291-302.
12. Ratanatharathorn V, Powers WE, Moss WT, et al. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999; 44: 1-18.
13. SOU 1998:128. 'Forskning 2000' (in Swedish). Statens offentliga utredningar 1998.
14. OECD. The measurement of scientific and technological activities; proposed standard practice for surveys of research and experimental development, OECD 1993.
15. Medical Research Council. Clinical research - crisis and costs (in Swedish). MFR Report 5; 1998.
16. Glatstein E. What is research? Int J Radiat Oncol Biol Phys 2001; 51: 288-90.
17. Grey Zone (GZ) group. The role and position of university hospitals (in Swedish). Stockholm: Karolinska Institutet; 1994.
18. van der Schueren E, Horiot JCI, Leunens G, et al. Quality assurance in cancer treatment. Report of a working party from the European School of Oncology. Eur J Cancer 1992; 29: 172-81.
19. Van Esch A, Bogaerts R, Kutcher GJ, et al. Quality assurance in radiotherapy by identifying standards and monitoring treatment preparation. Radiother Oncol 2000; 56: 109-15.
20. Ferreira IH, Dutreix A, Bridier A, et al. The ESTRO-QUALity assurance network (EQUAL). Radiother Oncol 2000; 55: 273-84.
21. Swedish Cancer Society. Investigation concerning clinical treatment studies. Cancerfonden 1999.
22. Dische S, Saunders M. Translational research - A new entity? Acta Oncol 2001; 40: 995-9.
23. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723.
24. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-604.
25. Haberkorn U. Positron emission tomography (PET) of non-small cell lung cancer. Lung Cancer 2001; 34 (Suppl 2): S115-21.
26. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001; 92: 886-95.
27. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000; 27: 1441-56.
28. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-93.
29. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 2001; 51: 923-31.
30. Leunens G, Menten J, Weltens C, et al. Quality assessment of medical decision making in radiation oncology: variability in target volume delineation for brain tumours. Radiother Oncol 1993; 29: 169-75.